Spots Global Cancer Trial Database for AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Official Title: A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia
Study ID: NCT02024308
Study Description
Brief Summary: The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with AML1-ETO acute myeloid leukemia.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Hematology, Changhai Hospital, Shanghai, , China
Contact Details
Name: Xianmin Song, Doctor
Affiliation: Department of Hematology, Changhai Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
